Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
FDA Orange Book
0
Canada
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Sofosbuvir Velpatasvir Drug Combination
2. Sofosbuvir, Velpatasvir Drug Combination
3. Sofosbuvir-velpatasvir Drug Combination
1. Sofosbuvir & Velpatasvir
2. Sofosbuvir + Velpatasvir
3. Epclusa Tablet
4. Sofosbuvir / Velpatasvir
5. Velpatasvir / Sofosbuvir
6. Sofosbuvir And Velpatasvir
7. Sof / Vlp
8. Sofosbuvir Mixture With Velpatasvir
9. S900007160
| Molecular Weight | 1412.5 g/mol |
|---|---|
| Molecular Formula | C71H83FN11O17P |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 21 |
| Rotatable Bond Count | 24 |
| Exact Mass | 1411.56900538 g/mol |
| Monoisotopic Mass | 1411.56900538 g/mol |
| Topological Polar Surface Area | 346 Ų |
| Heavy Atom Count | 101 |
| Formal Charge | 0 |
| Complexity | 2600 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 12 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older (see sections 4. 2, 4. 4 and 5. 1).
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
J05A
J - Antiinfectives for systemic use
J05 - Antivirals for systemic use
J05A - Direct acting antivirals
J05AP - Antivirals for treatment of hcv infections
J05AP55 - Sofosbuvir and velpatasvir
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Sofosbuvir and velpatasvir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sofosbuvir and velpatasvir, including repackagers and relabelers. The FDA regulates Sofosbuvir and velpatasvir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sofosbuvir and velpatasvir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Sofosbuvir and velpatasvir supplier is an individual or a company that provides Sofosbuvir and velpatasvir active pharmaceutical ingredient (API) or Sofosbuvir and velpatasvir finished formulations upon request. The Sofosbuvir and velpatasvir suppliers may include Sofosbuvir and velpatasvir API manufacturers, exporters, distributors and traders.
Sofosbuvir and velpatasvir Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sofosbuvir and velpatasvir GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sofosbuvir and velpatasvir GMP manufacturer or Sofosbuvir and velpatasvir GMP API supplier for your needs.
A Sofosbuvir and velpatasvir CoA (Certificate of Analysis) is a formal document that attests to Sofosbuvir and velpatasvir's compliance with Sofosbuvir and velpatasvir specifications and serves as a tool for batch-level quality control.
Sofosbuvir and velpatasvir CoA mostly includes findings from lab analyses of a specific batch. For each Sofosbuvir and velpatasvir CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sofosbuvir and velpatasvir may be tested according to a variety of international standards, such as European Pharmacopoeia (Sofosbuvir and velpatasvir EP), Sofosbuvir and velpatasvir JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sofosbuvir and velpatasvir USP).
LOOKING FOR A SUPPLIER?
